Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 6, 2026
Event: Entry into an Open Market Sale Agreement (At-the-Market Offering).
Key Financial Metrics
This filing does not report historical financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the potential capital raise:
- Maximum Offering Size: Up to $75.0 million in aggregate offering price.
- Commission: Up to 3.0% of gross proceeds payable to the agent (Jefferies LLC).
Material Changes
The material change reported is the execution of a Sales Agreement with Jefferies LLC, enabling the Company to sell shares of its common stock in "at-the-market" offerings. This provides a flexible mechanism to raise capital without a fixed issuance schedule or price.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: The Company intends to use net cash proceeds from the sale of shares for the following purposes:
- Clinical development of pelareorep.
- Associated research and development expenses.
- Operating costs.
- Working capital and general corporate purposes.
Terms: The Company is not obligated to sell any shares. The agreement may be terminated by either party upon ten trading days' notice.
Investor Verification Checklist
- Verify the current market price of ONCY common stock to estimate the number of shares potentially issuable under the $75.0 million cap.
- Review the effective shelf registration statement (Form S-3, File No. 333-294811) for existing share authorization limits.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Assess the impact of the 3.0% commission on net capital raised.